Ben Shepherd net worth
Quick answer
Ben Shepherd's estimated net worth is $5.65M (range $3.95M – $8.47M) as of 2026. Ben Shepherd is Founder at Trestle Biotherapeutics. Trestle Biotherapeutics valuation.
Ben Shepherd is Founder at Trestle Biotherapeutics (YC W21). Independent Entrepreneurial Check model estimate from public YC data.
At a glance
- Company status: Active
- Education: University of California, Berkeley
- Region: United States of America
- Industries: Healthcare, Industrial Bio
- Team size: 2
- Website: http://www.trestlebio.com
Who is Ben Shepherd?
Ben Shepherd is a co-founder of Trestle Biotherapeutics, a company that focuses on advancing biotherapeutic solutions.
Highlights:
- University of California, Berkeley
- Trestle Biotherapeutics
- Y Combinator W21
About Trestle Biotherapeutics
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but...
FAQ: Ben Shepherd net worth and Trestle Biotherapeutics valuation
What is Ben Shepherd's net worth?
Ben Shepherd's estimated net worth is $5.65M (range $3.95M – $8.47M) as of 2026. Ben Shepherd is Founder at Trestle Biotherapeutics. Entrepreneurial Check publishes an independent model-based estimate from public company and role data. Not verified net worth, and Entrepreneurial Check is not affiliated with Y Combinator or the profiled companies.
What is Trestle Biotherapeutics valuation?
Trestle Biotherapeutics's estimated valuation on Entrepreneurial Check is $11.3M. That valuation, or a disclosed round when one is public, is the source for the paper-wealth estimate. Independent model output — not a verified appraisal or official mark.
What is Ben Shepherd's role?
Ben Shepherd is Founder at Trestle Biotherapeutics, a Y Combinator-backed startup (batch W21).